Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile
Open Access
- 26 April 2024
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (9) , 2059-2073
Abstract
Novel therapies are needed for effective treatment of acute myeloid leukemia (AML). Relapse is common and salvage treatment with cytotoxic chemotherapy is rarely curative. CD123 and CD33, 2 clinically validated targets in AML, are jointly expressed on blasts and leukemic stem cells in >95% of patients with AML. However, their expression is heterogenous between subclones and between patients, which may affect the efficacy of single-targeting agents in certain patient populations. We present here a dual-targeting CD33/CD123 NANOBODY T-cell engager (CD33/CD123-TCE) that was designed to decrease the risk of relapse from possible single antigen-negative clones and to increase coverage within and across patients. CD33/CD123-TCE killed AML tumor cells expressing 1 or both antigens in vitro. Compared with single-targeting control compounds, CD33/CD123-TCE conferred equal or better ex vivo killing of AML blasts in most primary AML samples tested, suggesting a broader effectiveness across patients. In a disseminated cell-line–derived xenograft mouse model of AML, CD33/CD123-TCE cleared cancer cells in long bones and in soft tissues. As cytokine release syndrome is a well-documented adverse effect of TCE, the compound was tested in a cytokine release assay and shown to induce less cytokines compared to a CD123 single-targeting control. In an exploratory single-dose nonhuman primate study, CD33/CD123-TCE revealed a favorable PK profile. Depletion of CD123 and CD33 expressing cells was observed, but there were neither signs of cytokine release syndrome nor clinical signs of toxicity. Taken together, the CD33/CD123 dual-targeting NANOBODY TCE exhibits potent and safe anti-AML activity and promises a broad patient coverage.Keywords
This publication has 69 references indexed in Scilit:
- Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemiaBlood, 2006
- Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemiaBlood, 2005
- Detailed analysis of FLT3 expression levels in acute myeloid leukemia.2005
- C-Type Lectin-Like Molecule-1Cancer Research, 2004
- The Organizing Principle in the Formation of the T Cell Receptor-CD3 ComplexCell, 2002
- Elevated expression of IL-3Rα in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosisBlood, 2002
- The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cellsLeukemia, 2000
- Cytokine release and dynamics of leukocyte populations after CD3/TCR monoclonal antibody treatmentJournal of Clinical Immunology, 1992
- Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells.1991
- Activation of human thymocytes by antibodies to the CD3/T-cell receptor complex: Triggering of different epitopes results in different signalsCellular Immunology, 1991